Trial · NCT02175654
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival rate at 6 months | 6 months | |
| Secondary | Objective response rate based on the Response Evaluation Criteria in Solid Tumors criteria | 36 months | |
| Secondary | Disease control rate | 36 months | |
| Secondary | Response according other criteria (Appendix 9) | 36 months | |
| Secondary | Time to response | 36 months | |
| Secondary | Progression free survival | 36 months | |
| Secondary | Time to treatment failure | 36 months | |
| Secondary | Response duration | 36 months | |
| Secondary | Duration of stable disease | 36 months | |
| Secondary | Overall survival | 36 months | |
| Secondary | Time to progression | 36 months | |
| Secondary | Incidence and severity of adverse events (AE) (NCI CTC, version 3.0) | 36 months | |
| Secondary | Changes in laboratory values | baseline and end of treatment, an expected average of 4 months | hemoglobin, hematocrit, platelets, creatinine, total bilirubin, alkaline phosphatase, ALT, AST, BUN or urea, glucose, sodium, potassium, calcium, phosphorus, LDH, GGT, magnesium, albumin, total protein, uric acid and lipase. |
| Secondary | Change in vital signs (weight loss and hypertension) | baseline and end of treatment, an expected average of 4 months | |
| Secondary | Incidence of dose adjustments and compliance | 36 months | |
| Secondary | Incidence of concomitant medication | 36 months | |
| Secondary | Changes in ECOG performance status over time from baseline | baseline and end of treatment, an expected average of 4 months | |
| Other | microRNA expression level in the Peripheral Blood | 36 months | |
| Other | Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters. | 36 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02175654/registered